Abstract 2349
Background
Previous clinical trials demonstrated that alectinib (ALEC) produced fewer adverse events compared to crizotinib (CRZ). Data regarding adverse events (AE) in clinical practice, however, is limited. We reviewed ALK-rearranged NSCLC patients treated with crizotinib or alectinib in institutions of the West Japan Oncology Group, and the safety of CRZ and ALEC were evaluated using the real-world data.
Methods
We reviewed the clinical data of ALK-rearranged NSCLC patients who received CRZ or ALEC between May 2012 and Dec 2016. Patients were divided into two groups, the CRZ, or the ALEC group. To evaluate the safety of each ALK-inhibitor, we compared the AEs between the CRZ and the ALEC groups.
Results
Of 864 patients enrolled from 61 institutions, 840 patients were analyzed. Median age was 61 (range, 20-94); 56% were female; and 95% had adenocarcinoma. There was no significant difference in the frequencies of ILD, renal dysfunction, and digestive dysfunction between the CRZ and the ALEC groups.(p = 0.905, p = 0.7208, p = 0.1735) Meanwhile, liver dysfunction was significantly more frequent in the CRZ group compared to the ALEC group.(50.7% in CRZ group vs. 29.1% in ALEC group, p = 0.0313) In adverse events of grade 3 or more, liver dysfunction remained significantly different in frequency between the two groups.(13.3% in CRZ vs. 3.9% in ALEC, p < 0.0001) Discontinuation due to adverse event was shown to be in 21.1% in the CRZ group, and 6.9% in the ALEC group.(p = 0.0656) Seventy-nine patients received alectinib therapy after the discontinuation of crizotinib due to an adverse event, with progression-free survival (PFS) of 24.8 months.
Conclusions
In clinical practice, the patients treated with CRZ exhibited a trend to discontinue CRZ at a higher rate due to AE compared to the ALEC group. The PFS of patients treated with ALEC, even in the patients who experience AE due to CRZ, was more than 2 years.
Clinical trial identification
UMIN000028605.
Editorial acknowledgement
Legal entity responsible for the study
Nobuyuki Yamamoto.
Funding
Pfizer.
Disclosure
K. Ito: Honoraria (self): Pfizer; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Speaker Bureau / Expert testimony: Chugai; Honoraria (self): Eli Lilly; Honoraria (self): MSD; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Kyorin; Research grant / Funding (institution): Daiichi-Sankyo. T. Yamanaka: Honoraria (self), Research grant / Funding (self): Takeda; Honoraria (self): Chugai; Honoraria (self), Research grant / Funding (self): Taiho; Honoraria (self): Boehringer Ingelheim; Advisory / Consultancy: Giiead Sciences; Advisory / Consultancy: Bayer. D. Fujimoto: Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self): Ono Pharmaceutical; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): Taiho Pharmaceutical Co; Honoraria (self): Chugai Pharmaceutical Co; Honoraria (self): MSD KK; Honoraria (self): Boehringer Ingelheim Japan Inc; Honoraria (self): Eli Lilly Japan KK,. M. Mori: Honoraria (institution), Speaker Bureau / Expert testimony: Chugai. H. Tanaka: Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant / Funding (institution): Eli Lilly; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Taiho pharmaceuticals; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Novartis; Honoraria (self), Research grant / Funding (institution): Ono pharmaceuticals; Honoraria (self), Research grant / Funding (institution): Chugai pharmaceuticals; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Research grant / Funding (institution): Takeda pharmaceuticals; Research grant / Funding (institution): Merck Serono. S. Teraoka: Honoraria (self): Chugai Pharmaceutical. O. Hataji: Honoraria (self): Chugai; Honoraria (self): Pfizer; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self), Research grant / Funding (institution): Boerhringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Daiichi-Sankyo; Honoraria (self), Research grant / Funding (institution): Kyorin; Honoraria (self): Eli Lilly. A. Bessho: Honoraria (self), Speaker Bureau / Expert testimony: Chugai Pharmaceutical Co., Ltd.; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (institution): Pfizer Japan Inc. A. Kubo: Honoraria (self), Research grant / Funding (self): Boehringer Ingerheim; Honoraria (self), Research grant / Funding (self): Chugai; Honoraria (self), Research grant / Funding (self): Eli Lilly; Honoraria (self): MSD; Honoraria (self), Research grant / Funding (self): Novartis; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (self): Ono Pharma. K. Nakagawa: Honoraria (self), Advisory / Consultancy: Astellas Pharma; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Takeda Pharmaceutical; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Chugai; Honoraria (self), Research grant / Funding (institution): MSD; Honoraria (self), Research grant / Funding (institution): Eli Lilly; Honoraria (self), Research grant / Funding (institution): Ono Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Boehringer Ingelheim; Honoraria (self), Research grant / Funding (institution): Daiichi Sankyo; Honoraria (self), Research grant / Funding (institution): Novartis Pharma; Honoraria (self), Research grant / Funding (institution): Taiho Pharmaceutical; Honoraria (self), Research grant / Funding (institution): Pfizer Japan; Honoraria (self), Research grant / Funding (institution): Bristol-Myers Squibb Company; Honoraria (self): KYORIN Pharmaceutical; Honoraria (self): MEDICUS SHUPPAN,Publishers; Honoraria (self): Thermo Fisher Scientific K.K; Honoraria (self): Nichi-Iko Pharmaceutical ; Honoraria (self): Hisamitsu Pharmaceutical; Research grant / Funding (institution): Eisai Co; Research grant / Funding (institution): PAREXEL International Corp. N. Yamamoto: Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self), Research grant / Funding (institution): Chugai. All other authors have declared no conflicts of interest.
Resources from the same session
3181 - Effects of Three Products in the Prevention and Treatment of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
Presenter: Francesca Zannier
Session: Poster Display session 1
Resources:
Abstract
2433 - Boiling Histotripsy-induced Mechanical Ablation Modulates Tumour Microenvironment by Promoting Immunogenic Cell Death of Cancers
Presenter: Cheol-Hee Shin
Session: Poster Display session 1
Resources:
Abstract
2663 - The bacterial receptor NOD2 mediates LGR5+ intestinal stem cells protection against irradiation via mitophagy activation
Presenter: Antonin Levy
Session: Poster Display session 1
Resources:
Abstract
3213 - Pulse mode irradiation regimen of PDT results in high progression free and overall survival in mice with model tumor
Presenter: Alexey Bogdanov
Session: Poster Display session 1
Resources:
Abstract
3722 - Proton-sensitizing effect of small molecule inhibitor of P300 histone acetyltransferase C646 in human pancreatic cancer cells.
Presenter: Sungwon Shin
Session: Poster Display session 1
Resources:
Abstract
5805 - Red-Blood-Cell-Membrane-Enveloped Magnetic Nanoclusters as a Biomimetic Theranostic Nanoplatform for Bimodal Imaging Guided Cancer Photothermal Therapy
Presenter: sheng wang
Session: Poster Display session 1
Resources:
Abstract
5251 - Urine cell-free and extracellular vesicle cargo miRNAs as biomarkers for prostate cancer diagnosis
Presenter: Ivan Zaporozhchenko
Session: Poster Display session 1
Resources:
Abstract
3657 - Parkin, APEX1 and BCL2L1 Tissue Expression in Southern Brazilian Patients with Different Breast Cancer Molecular Subtypes
Presenter: Bianca Cabral
Session: Poster Display session 1
Resources:
Abstract
2839 - Obesity and prognosis in breast cancer
Presenter: Noha Ibrahim
Session: Poster Display session 1
Resources:
Abstract
5132 - SIPA1 is a modulator of HGF induced tumor metastasis via the regulation of tight junctions in lung adenocarcinoma cells
Presenter: Chang Liu
Session: Poster Display session 1
Resources:
Abstract